Literature DB >> 11399777

Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling.

Q Tao1, M V Backer, J M Backer, B I Terman.   

Abstract

The vascular endothelial growth factor (VEGF) receptor tyrosine kinase subtype kinase insert domain receptor (KDR) contains seven extracellular Ig-like domains, of which the three most amino-terminal contain the necessary structural features required for VEGF binding. To clarify the functional role of KDR Ig-like domains 4-7, we compared VEGF-induced signaling in human embryonic kidney and porcine aortic endothelial cells expressing native versus mutant receptor proteins in which Ig-like domains 4-7, 4-6, or 7 had been deleted. Western blotting using an anti-receptor antibody indicated equivalent expression levels for each of the recombinant proteins. As expected, VEGF treatment robustly augmented native receptor autophosphorylation. In contrast, receptor autophosphorylation, as well as downstream signaling events, were VEGF-independent for cells expressing mutant receptors. (125)I-VEGF(165) bound with equal or better affinity to mutant versus native receptor, although the number of radioligand binding sites was significantly reduced because a significant percentage of mutant, but not native, receptors were localized to the cell interior. As was the case for native KDR, (125)I-VEGF(165) binding to the mutant receptors was dependent upon cell surface heparan sulfate proteoglycans, and (125)I-VEGF(121) bound with an affinity equal to that of (125)I-VEGF(165) to the native and mutant receptors. It is concluded that KDR Ig-like domains 4-7 contain structural features that inhibit receptor signaling by a mechanism that is independent of neuropilin-1 and heparan sulfate proteoglycans. We speculate that this provides a cellular mechanism for blocking unwanted signaling events in the absence of VEGF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399777     DOI: 10.1074/jbc.M100763200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites.

Authors:  Caroline A C Hyde; Alexandra Giese; Edward Stuttfeld; Johan Abram Saliba; Denis Villemagne; Thomas Schleier; H Kaspar Binz; Kurt Ballmer-Hofer
Journal:  Mol Cell Biol       Date:  2012-07-16       Impact factor: 4.272

2.  Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis.

Authors:  P Chiodelli; S Rezzola; C Urbinati; F Federici Signori; E Monti; R Ronca; M Presta; M Rusnati
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

3.  Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling.

Authors:  Fabiola Cecchi; Deborah Pajalunga; C Andrew Fowler; Aykut Uren; Daniel C Rabe; Benedetta Peruzzi; Nicholas J Macdonald; Davida K Blackman; Stephen J Stahl; R Andrew Byrd; Donald P Bottaro
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

4.  PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.

Authors:  Tatsuya Ozawa; Cameron W Brennan; Lu Wang; Massimo Squatrito; Takashi Sasayama; Mitsutoshi Nakada; Jason T Huse; Alicia Pedraza; Satoshi Utsuki; Yoshie Yasui; Adesh Tandon; Elena I Fomchenko; Hidehiro Oka; Ross L Levine; Kiyotaka Fujii; Marc Ladanyi; Eric C Holland
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

5.  Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.

Authors:  Lokesh Jain; Tristan M Sissung; Romano Danesi; Elise C Kohn; William L Dahut; Shivaani Kummar; David Venzon; David Liewehr; Bevin C English; Caitlin E Baum; Robert Yarchoan; Giuseppe Giaccone; Jürgen Venitz; Douglas K Price; William D Figg
Journal:  J Exp Clin Cancer Res       Date:  2010-07-14

Review 6.  Emerging roles of post-translational modifications in signal transduction and angiogenesis.

Authors:  Nader Rahimi; Catherine E Costello
Journal:  Proteomics       Date:  2014-10-08       Impact factor: 3.984

Review 7.  Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

Authors:  Megan Li; Deanna L Kroetz
Journal:  Pharmacol Ther       Date:  2017-09-04       Impact factor: 12.310

Review 8.  Vascular endothelial growth factor A: just one of multiple mechanisms for sex-specific vascular development within the testis?

Authors:  Kevin M Sargent; Renee M McFee; Renata Spuri Gomes; Andrea S Cupp
Journal:  J Endocrinol       Date:  2015-10-15       Impact factor: 4.286

9.  Dimerization of VEGF receptors and implications for signal transduction: a computational study.

Authors:  Feilim Mac Gabhann; Aleksander S Popel
Journal:  Biophys Chem       Date:  2007-03-24       Impact factor: 2.352

Review 10.  Molecular and functional diversity of vascular endothelial growth factors.

Authors:  Yasuo Yamazaki; Takashi Morita
Journal:  Mol Divers       Date:  2006-11       Impact factor: 3.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.